Natalizumab Temporary Discontinuation Study
NCT02775110
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Multiple Sclerosis
Interventions
OTHER:
Natalizumab discontinuation
Sponsor
University at Buffalo